Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
2003 1
2004 2
2005 1
2006 1
2007 2
2008 1
2009 1
2010 4
2011 3
2012 2
2013 5
2014 2
2015 12
2016 6
2017 8
2018 6
2019 8
2020 14
2021 17
2022 21
2023 16
2024 29
2025 36
2026 27

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Results by year

Filters applied: . Clear all
Page 1
Evidence-based guidelines for the pharmacological treatment of migraine.
Ornello R, Caponnetto V, Ahmed F, Al-Khazali HM, Ambrosini A, Ashina S, Baraldi C, Bellotti A, Brighina F, Calabresi P, Casillo F, Cevoli S, Cheng S, Chiang CC, Chiarugi A, Christensen RH, Chu MK, Coppola G, Corbelli I, Crema S, De Icco R, de Tommaso M, Di Lorenzo C, Di Stefano V, Diener HC, Ekizoğlu E, Fallacara A, Favoni V, Garces KN, Geppetti P, Goicochea MT, Granato A, Granella F, Guerzoni S, Ha WS, Hassan A, Hirata K, Hoffmann J, Hüssler EM, Hussein M, Iannone LF, Jenkins B, Labastida-Ramirez A, Laporta A, Levin M, Lupica A, Mampreso E, Martinelli D, Monteith TS, Orologio I, Özge A, Pan LH, Panneerchelvam LL, Peres MFP, Souza MNP, Pozo-Rosich P, Prudenzano MP, Quattrocchi S, Rainero I, Romanenko V, Romozzi M, Russo A, Sances G, Sarchielli P, Schwedt TJ, Silvestro M, Swerts DB, Tassorelli C, Tessitore A, Togha M, Vaghi G, Wang SJ, Ashina M, Sacco S. Ornello R, et al. Cephalalgia. 2025 Apr;45(4):3331024241305381. doi: 10.1177/03331024241305381. Epub 2025 Apr 25. Cephalalgia. 2025. PMID: 40277319 Free article.
Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM. AbouEzzeddine OF, et al. JAMA Cardiol. 2021 Nov 1;6(11):1267-1274. doi: 10.1001/jamacardio.2021.3070. JAMA Cardiol. 2021. PMID: 34431962 Free PMC article.

Prevalence increased with age from 0% in patients 60 to 69 years of age to 21% in patients 90 years and older (P < .001). Adjusting for age, ATTR-CM prevalence differed by sex, with 15 of 149 men (10.1%; 95% CI, 5.7%-16.1%) and 3 of 137 women (2.2%; 95% CI, 0.4%-6.3%) h

…

Prevalence increased with age from 0% in patients 60 to 69 years of age to 21% in patients 90 years and older (P < .001). Adjustin

…
Modulation of NLRP3 inflammasome-related-inflammation via RIPK1/RIPK3-DRP1 or HIF-1α signaling by phenothiazine in hypothermic and normothermic neuroprotection after acute ischemic stroke.
Jiang Q, Ding Y, Li F, Fayyaz AI, Duan H, Geng X. Jiang Q, et al. Redox Biol. 2024 Jul;73:103169. doi: 10.1016/j.redox.2024.103169. Epub 2024 Apr 26. Redox Biol. 2024. PMID: 38692093 Free PMC article.
Overexpression of RIPK1, RIPK3, DRP-1, NLRP3-inflammasome and cytochrome c-apoptosis were all significantly reduced by C + P at 33 C and the RIPK1 inhibitor (Nec1s), suggesting hypothermic effect of C + P via RIPK1/RIPK3-DRP1pathway. ...These were also evidenced in …
Overexpression of RIPK1, RIPK3, DRP-1, NLRP3-inflammasome and cytochrome c-apoptosis were all significantly reduced by C + P at 33 C …
Frataxin deficiency promotes endothelial senescence in pulmonary hypertension.
Culley MK, Zhao J, Tai YY, Tang Y, Perk D, Negi V, Yu Q, Woodcock CC, Handen A, Speyer G, Kim S, Lai YC, Satoh T, Watson AM, Aaraj YA, Sembrat J, Rojas M, Goncharov D, Goncharova EA, Khan OF, Anderson DG, Dahlman JE, Gurkar AU, Lafyatis R, Fayyaz AU, Redfield MM, Gladwin MT, Rabinovitch M, Gu M, Bertero T, Chan SY. Culley MK, et al. J Clin Invest. 2021 Jun 1;131(11):e136459. doi: 10.1172/JCI136459. J Clin Invest. 2021. PMID: 33905372 Free PMC article.
Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction.
Fayyaz AU, Edwards WD, Maleszewski JJ, Konik EA, DuBrock HM, Borlaug BA, Frantz RP, Jenkins SM, Redfield MM. Fayyaz AU, et al. Circulation. 2018 Apr 24;137(17):1796-1810. doi: 10.1161/CIRCULATIONAHA.117.031608. Epub 2017 Dec 15. Circulation. 2018. PMID: 29246894 Free PMC article.
RESULTS: The average arterial percent medial thickness (control, 6.9; HF-PH, 11.0; PVOD, 15.0), arterial %IT (control, 4.9; HF-PH, 14.9; PVOD, 31.1), venous %IT (control, 14.0; HF-PH, 24.9; PVOD, 43.9), and IV %IT (control, 10.6; HF-PH, 25.8; PVOD, 50.0) in HF-PH were higher than …
RESULTS: The average arterial percent medial thickness (control, 6.9; HF-PH, 11.0; PVOD, 15.0), arterial %IT (control, 4.9; HF-PH, 14.9; PVO …
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektassov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, de Jong BC, Dinh LV, Ferlazzo G, Kirakosyan O, Lachenal N, Lecca L, McIlleron H, Mikanda KK, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Nguyen DV, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Pham TH, Phan DT, Phan HTT, Phillips PPJ, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung KJ, Asfaw MT, Vargas Vasquez D, Rich ML, Varaine F, Mitnick CD; endTB-Q Clinical Trial Team. Guglielmetti L, et al. Lancet Respir Med. 2025 Sep;13(9):809-820. doi: 10.1016/S2213-2600(25)00194-8. Epub 2025 Jul 16. Lancet Respir Med. 2025. PMID: 40683298 Free article. Clinical Trial.
At week 73, favourable outcome was reached by 141 (87%) participants in the BDLC group versus 75 (89%) in the control group in the mITT population (adjusted risk difference 0.2% [95% CI -9.1 to 9.5]; p(non-inferiority)=0.0051) and by 138 (88%) of 157 versus 71 (93%) of 76 …
At week 73, favourable outcome was reached by 141 (87%) participants in the BDLC group versus 75 (89%) in the control group in the mITT popu …
Clinical outcomes of peroral endoscopic myotomy with and without septotomy for management of epiphrenic diverticula: an international multicenter experience (with video).
Shrigiriwar A, Mony S, Fayyaz F, Onimaru M, Monachese M, Zhang L, Corre F, Azmeera P, Wu H, Wu CCH, Choi K, Gandhi A, Chalikonda D, Keane MG, Ghandour B, Villamarin-Corrales J, Schlachterman A, Tinto RR, Arévalo FE, Arbizu EA, Bapaye A, Velanovich V, Nieto J, Pawa R, Pawa S, Samanta J, Sedarat A, Eleftheriadis N, Saxena P, Bechara R, Al-Haddad MA, Familiari P, Ujiki M, Ramchandani M, Barret M, Chang K, Moll F, Pioche M, Inoue H, Khashab M. Shrigiriwar A, et al. Gastrointest Endosc. 2024 Nov;100(5):840-848.e4. doi: 10.1016/j.gie.2024.05.010. Epub 2024 May 23. Gastrointest Endosc. 2024. PMID: 38795736
Patients in the POEM+S group had a significantly higher mean pre-POEM ES (7.3 2.1 vs 5.8 2; P = .002). The most common indication for POEM was achalasia (51% in the POEM+S cohort and 51.8% in the POEM-S cohort; P = .7). A posterior approach was favored in the PO …
Patients in the POEM+S group had a significantly higher mean pre-POEM ES (7.3 2.1 vs 5.8 2; P = .002). The most common indication …
Safety and equity in scaling minimally invasive surgery worldwide in 109 countries using cholecystectomy as a tracer procedure: a prospective cohort study.
NIHR Global Health Research Unit on Global Surgery and the GlobalSurg Collaborative. NIHR Global Health Research Unit on Global Surgery and the GlobalSurg Collaborative. Lancet Glob Health. 2026 Feb;14(2):e199-e212. doi: 10.1016/S2214-109X(25)00476-0. Lancet Glob Health. 2026. PMID: 41519150 Free article.
Three modifiable hospital-level factors were strongly associated with safer outcomes: establishment of local simulation-based training facilities (adjusted OR 0.78 [0.71-0.86]; p<0.0001), adoption of intraoperative safety and communication strategies (0.87 [0.79-0.96]; …
Three modifiable hospital-level factors were strongly associated with safer outcomes: establishment of local simulation-based training facil …
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas.
Bhansali RS, Ellin F, Relander T, Cao M, Li W, Long Q, Ganesan N, Stuver R, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez J, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain JM, Ruiz M, Brammer JE, Prakash R, Iyer SP, Olszewski AJ, Major A, Riedell PA, Smith SM, Goldin C, Haverkos B, Hu B, Zhuang TZ, Allen PB, Toama W, Janakiram M, Brooks TR, Jagadeesh D, Hariharan N, Goodman AM, Hartman G, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. Bhansali RS, et al. Blood Adv. 2024 Jul 9;8(13):3507-3518. doi: 10.1182/bloodadvances.2024012800. Blood Adv. 2024. PMID: 38739715 Free PMC article.
Validation set patients with low-risk (n = 158) and high-risk (n = 188) CITI scores had a 10-year cumulative risk of CNS relapse of 2.2% and 13.4%, respectively (hazard ratio, 5.24; 95% confidence interval, 1.50-18.26; P = .018). We developed an open-access web-based CITI …
Validation set patients with low-risk (n = 158) and high-risk (n = 188) CITI scores had a 10-year cumulative risk of CNS relapse of 2.2% and …
196 results